How To Respond When FDA Knocks

Law360, New York (September 26, 2013, 4:49 PM EDT) -- Recently, the U.S. Food and Drug Administration issued a draft guidance entitled, “Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug Inspection.”[1] Congress required the FDA to issue this guidance within a year of the enactment of the Food and Drug Administration Safety and Innovation Act (FDASIA), which strengthened the FDA’s authority regarding inspection refusals so that now delaying, denying, limiting or refusing to permit inspection causes a drug to be adulterated. 21 U.S.C. § 351(j) (a drug is adulterated if “it has been manufactured,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.